{"id":12695,"date":"2022-01-28T14:50:46","date_gmt":"2022-01-28T13:50:46","guid":{"rendered":"https:\/\/kapitalpartner.dk\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/"},"modified":"2022-02-26T12:29:06","modified_gmt":"2022-02-26T11:29:06","slug":"virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/","title":{"rendered":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST"},"content":{"rendered":"\n

ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body. It is possible to measure the protein in the blood of everyone. In the beginning of December, the company announced that the Innovation Fund has been assigned a so-called Innobooster grant of DKK 2.8 million for the continued work of developing, testing and subsequently launching a point-of-care product (suPARnostic POC).<\/p>\n\n

The POC product must be able to test both the biomarker suPAR and another biomarker called CRP in less than 10 minutes, which, like suPAR, gives an indication of the level of inflammation in the body. The product must therefore be able to be used as a test in ambulances and in medical practice to quickly assess whether patients should be admitted or not.<\/p>\n\n

The higher the suPAR levels, the more ill you become compared to people with low suPAR levels. Thus, suPAR levels of respectively below 4ng\/ml, between 4-6ng\/ml, and above 6ng\/ml can identify critical patients with a low, medium or high risk of mortality within 30- and 90 days.<\/p>\n\n

The POC product was supposed to be launched in 2021 but has been postponed until Q2\u20192022. The POC product was supposed to be launched in 2021 but has been postponed until Q2\u20192022. The delay is related to general analytical performance parameters and a detailed review of development plans with ViroGates’ Austrian partner Genspeed Biotech.<\/p>\n","protected":false},"excerpt":{"rendered":"

ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body. It is possible to measure the protein in the blood of everyone. In the beginning of December, the company announced that the Innovation Fund has been assigned a so-called Innobooster grant of DKK 2.8 million […]<\/p>\n","protected":false},"author":7,"featured_media":9361,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[151],"tags":[152],"class_list":["post-12695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-cases","tag-virogates-en"],"acf":[],"yoast_head":"\nVIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S<\/title>\n<meta name=\"description\" content=\"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-28T13:50:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-26T11:29:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"562\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank H. Andersen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank H. Andersen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\"},\"author\":{\"name\":\"Frank H. Andersen\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be\"},\"headline\":\"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST\",\"datePublished\":\"2022-01-28T13:50:46+00:00\",\"dateModified\":\"2022-02-26T11:29:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\"},\"wordCount\":244,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg\",\"keywords\":[\"ViroGates\"],\"articleSection\":[\"Company cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\",\"name\":\"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg\",\"datePublished\":\"2022-01-28T13:50:46+00:00\",\"dateModified\":\"2022-02-26T11:29:06+00:00\",\"description\":\"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg\",\"width\":800,\"height\":562},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Company cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be\",\"name\":\"Frank H. Andersen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g\",\"caption\":\"Frank H. Andersen\"},\"sameAs\":[\"Zim\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S","description":"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/","og_locale":"en_US","og_type":"article","og_title":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S","og_description":"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.","og_url":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-01-28T13:50:46+00:00","article_modified_time":"2022-02-26T11:29:06+00:00","og_image":[{"width":800,"height":562,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg","type":"image\/jpeg"}],"author":"Frank H. Andersen","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Frank H. Andersen","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/"},"author":{"name":"Frank H. Andersen","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be"},"headline":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST","datePublished":"2022-01-28T13:50:46+00:00","dateModified":"2022-02-26T11:29:06+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/"},"wordCount":244,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg","keywords":["ViroGates"],"articleSection":["Company cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/","url":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/","name":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg","datePublished":"2022-01-28T13:50:46+00:00","dateModified":"2022-02-26T11:29:06+00:00","description":"ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body.","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/12\/ViroGates.jpg","width":800,"height":562},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/virogates-modtager-dkk-2-8-mio-til-faerdiggoerelse-af-fingerprik-testen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Company cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/"},{"@type":"ListItem","position":3,"name":"VIROGATES RECEIVES DKK 2.8 MILLION TO COMPLETE THE FINGER PRICK TEST"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/bfe85c5979b5e2bb7babb4edc8a674be","name":"Frank H. Andersen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eb82938c73dcfb21254022c376889d0d?s=96&d=mm&r=g","caption":"Frank H. Andersen"},"sameAs":["Zim"]}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/12695"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=12695"}],"version-history":[{"count":5,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/12695\/revisions"}],"predecessor-version":[{"id":13096,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/12695\/revisions\/13096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/9361"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=12695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=12695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=12695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}